{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:58:17Z","timestamp":1791921497159,"version":"4.3.4"},"reference-count":127,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Ibrexafungerp (formerly SCY-078 or MK-3118) is a first-in-class triterpenoid antifungal or \u201cfungerp\u201d that inhibits biosynthesis of \u03b2-(1,3)-D-glucan in the fungal cell wall, a mechanism of action similar to that of echinocandins. Distinguishing characteristics of ibrexafungerp include oral bioavailability, a favourable safety profile, few drug\u2013drug interactions, good tissue penetration, increased activity at low pH and activity against multi-drug resistant isolates including C. auris and C. glabrata. In vitro data has demonstrated broad and potent activity against Candida and Aspergillus species. Importantly, ibrexafungerp also has potent activity against azole-resistant isolates, including biofilm-forming Candida spp., and echinocandin-resistant isolates. It also has activity against the asci form of Pneumocystis spp., and other pathogenic fungi including some non-Candida yeasts and non-Aspergillus moulds. In vivo data have shown IBX to be effective for treatment of candidiasis and aspergillosis. Ibrexafungerp is effective for the treatment of acute vulvovaginal candidiasis in completed phase 3 clinical trials.<\/jats:p>","DOI":"10.3390\/jof7030163","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T02:08:17Z","timestamp":1614305297000},"page":"163","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":123,"title":["Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor"],"prefix":"10.3390","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4436-5517","authenticated-orcid":false,"given":"Sabelle","family":"Jallow","sequence":"first","affiliation":[{"name":"Centre for Healthcare-Associated Infections, Antimicrobial Resistance and Mycoses (CHARM), National Institute for Communicable Diseases, a Division of the National Health Laboratory Service, Johannesburg 2131, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7869-9462","authenticated-orcid":false,"given":"Nelesh P.","family":"Govender","sequence":"additional","affiliation":[{"name":"Centre for Healthcare-Associated Infections, Antimicrobial Resistance and Mycoses (CHARM), National Institute for Communicable Diseases, a Division of the National Health Laboratory Service, Johannesburg 2131, South Africa"},{"name":"School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/mmy.39.1.55.66","article-title":"Fungal beta(1,3)-D-glucan synthesis","volume":"39","author":"Douglas","year":"2001","journal-title":"Med. Mycol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/jac\/46.3.485","article-title":"In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide","volume":"46","author":"Mikamo","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","article-title":"Echinocandin antifungal drugs","volume":"362","author":"Denning","year":"2003","journal-title":"Lancet"},{"key":"ref_4","unstructured":"Merck Research Laboratories (2020, December 29). Cancidas (Caspofungin Acetate) Injection. Application No.: 21-227. Approval Date: 26 January 2001. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Special Pathogen and Immunologic Drug Products, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2001\/21227_Cancidas.cfm."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1086\/317614","article-title":"The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans","volume":"182","author":"Feldmesser","year":"2000","journal-title":"J. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0065-3233(01)56011-8","article-title":"Glucan synthase inhibitors as antifungal agents","volume":"56","author":"Kurtz","year":"2001","journal-title":"Adv. Protein Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1086\/501020","article-title":"Micafungin: A new echinocandin","volume":"42","author":"Chandrasekar","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1086\/505204","article-title":"Anidulafungin: A novel echinocandin","volume":"43","author":"Vazquez","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0723-2020(00)80062-4","article-title":"The discovery of enfumafungin, a novel antifungal compound produced by an endophytic Hormonema species biological activity and taxonomy of the producing organisms","volume":"23","author":"Pelaez","year":"2000","journal-title":"Syst. Appl. Microbiol."},{"key":"ref_10","unstructured":"PubChem [Internet] (2020, December 30). Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-.PubChem Compound Summary, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"8469","DOI":"10.1039\/C5TB00961H","article-title":"Surface coatings with covalently attached caspofungin are effective in eliminating fungal pathogens","volume":"3","author":"Coad","year":"2015","journal-title":"J. Mater. Chem. B"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1128\/AAC.44.2.368-377.2000","article-title":"Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors","volume":"44","author":"Onishi","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/mmy\/myz083","article-title":"Ibrexafungerp: A novel oral glucan synthase inhibitor","volume":"58","author":"Davis","year":"2020","journal-title":"Med. Mycol."},{"key":"ref_14","unstructured":"Azie, N. (November, January 31). A Phase 2b, Dose Finding Study Evaluating Oral Ibrexafungerp in Moderate to Severe Acute Vulvovaginal Candidiasis (DOVE). Proceedings of the 3rd ISIDOG Congress, Porto, Portugal. Available online: https:\/\/www.scynexis.com\/science\/publications-and-presentations\/posters-and-presentations?page=2."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Apgar, J.M., Wilkening, R.R., Parker, D.L., Meng, D., Wildonger, K.J., Sperbeck, D., Greenlee, M.L., Balkovec, J.M., Flattery, A.M., and Abruzzo, G.K. (2020). Ibrexafungerp: An orally active beta-1,3-glucan synthesis inhibitor. Bioorg. Med. Chem. Lett.","DOI":"10.1016\/j.bmcl.2020.127661"},{"key":"ref_16","unstructured":"Scynexis (2020, December 29). The World Health Organization Recognizes New Antifungal Class by Granting \u201cibrexafungerp\u201d to SCYNEXIS as the International Non-Proprietary Name for SCY-078. SCYNEXIS, Inc. Press Release Online. Available online: https:\/\/ir.scynexis.com\/press-releases\/detail\/156\/the-world-health-organization-recognizes-new-antifungal."},{"key":"ref_17","first-page":"2993","article-title":"The Fungal Cell Wall: Candida, Cryptococcus, and Aspergillus Species","volume":"10","author":"Rivera","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"100022","DOI":"10.1016\/j.tcsw.2019.100022","article-title":"Cell wall glucans of fungi. A review","volume":"5","year":"2019","journal-title":"Cell Surf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/978-1-4613-9547-8_2","article-title":"Composition and structure of yeast cell walls","volume":"1","author":"Fleet","year":"1985","journal-title":"Curr. Top Med. Mycol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1086\/375080","article-title":"Caspofungin","volume":"36","author":"Deresinski","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2958.2007.05872.x","article-title":"The cell wall: A carbohydrate armour for the fungal cell","volume":"66","author":"Latge","year":"2007","journal-title":"Mol. Microbiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1128\/MCB.15.10.5671","article-title":"Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase","volume":"15","author":"Mazur","year":"1995","journal-title":"Mol. Cell Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/yea.866","article-title":"Mutations in Fks1p affect the cell wall content of beta-1,3- and beta-1,6-glucan in Saccharomyces cerevisiae","volume":"19","author":"Dijkgraaf","year":"2002","journal-title":"Yeast"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7734","DOI":"10.1128\/jb.179.24.7734-7741.1997","article-title":"Cloning of the RHO1 gene from Candida albicans and its regulation of beta-1,3-glucan synthesis","volume":"179","author":"Kondoh","year":"1997","journal-title":"J. Bacteriol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S0021-9258(19)86116-1","article-title":"Biosynthesis of the yeast cell wall. I. Preparation and properties of beta-(1 leads to 3) glucan synthetase","volume":"255","author":"Shematek","year":"1980","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/AAC.01588-12","article-title":"In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods","volume":"57","author":"Pfaller","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1128\/AAC.00432-11","article-title":"Discovery of a novel class of orally active antifungal beta-1,3-D-glucan synthase inhibitors","volume":"55","author":"Walker","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Scorneaux, B., Angulo, D., Borroto-Esoda, K., Ghannoum, M., Peel, M., and Wring, S. (2017). SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.01961-16"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1128\/AAC.46.9.3001-3012.2002","article-title":"The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro","volume":"46","author":"Bowman","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ghannoum, M., Long, L., Larkin, E.L., Isham, N., Sherif, R., Borroto-Esoda, K., Barat, S., and Angulo, D. (2018). Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive Aspergillosis. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.00244-18"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Jimenez-Ortigosa, C., Perez, W.B., Angulo, D., Borroto-Esoda, K., and Perlin, D.S. (2017). De Novo Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.00833-17"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.drup.2007.04.002","article-title":"Resistance to echinocandin-class antifungal drugs","volume":"10","author":"Perlin","year":"2007","journal-title":"Drug Resist. Updat."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1128\/AAC.00443-09","article-title":"Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: Implication for the existing susceptibility breakpoint","volume":"53","author":"Lee","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1128\/AAC.49.8.3264-3273.2005","article-title":"Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates","volume":"49","author":"Park","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/infdis\/jir351","article-title":"Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance","volume":"204","author":"Lewis","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/cit136","article-title":"Increasing echinocandin resistance in Candida glabrata: Clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations","volume":"56","author":"Alexander","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1128\/AAC.03255-14","article-title":"Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance","volume":"58","author":"Pham","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/jac\/dkx480","article-title":"A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: Role of the ERG11 and FKS1 genes in azole and echinocandin resistance","volume":"73","author":"Chowdhary","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Kordalewska, M., Lee, A., Park, S., Berrio, I., Chowdhary, A., Zhao, Y., and Perlin, D.S. (2018). Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.00238-18"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mmcr.2016.03.004","article-title":"Two echinocandin-resistant Candida glabrata FKS mutants from South Africa","volume":"11","author":"Naicker","year":"2016","journal-title":"Med. Mycol. Case Rep."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Nunnally, N.S., Etienne, K.A., Angulo, D., Lockhart, S.R., and Berkow, E.L. (2019). In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.01692-19"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrd.2017.46","article-title":"The antifungal pipeline: A reality check","volume":"16","author":"Perfect","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/504490","article-title":"Invasive Fungal Pathogens: Current Epidemiological Trends","volume":"43","author":"Pfaller","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"165rv113","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden killers: Human fungal infections","volume":"4","author":"Brown","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_45","unstructured":"WHO (2014). Antimicrobial Resistance: Global Report on Surveillance, WHO (World Health Organization). Available online: https:\/\/www.who.int\/drugresistance\/documents\/surveillancereport\/en\/."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/1469-0691.12513","article-title":"Update on antifungal resistance in Aspergillus and Candida","volume":"20","author":"Arendrup","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1128\/JCM.42.10.4419-4431.2004","article-title":"Rare and emerging opportunistic fungal pathogens: Concern for resistance beyond Candida albicans and Aspergillus fumigatus","volume":"42","author":"Pfaller","year":"2004","journal-title":"J. Clin. Microbiol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Wickes, B.L. (2020). Analysis of a Candida auris Outbreak Provides New Insights into an Emerging Pathogen. J. Clin. Microbiol., 58.","DOI":"10.1128\/JCM.02083-19"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.3201\/eid2509.190040","article-title":"Epidemiologic Shift in Candidemia Driven by Candida auris, South Africa, 2016\u20132017(1)","volume":"25","author":"Mpembe","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1093\/jac\/dkw091","article-title":"Emergence of azole-resistant Candida parapsilosis causing bloodstream infection: Results from laboratory-based sentinel surveillance in South Africa","volume":"71","author":"Govender","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1128\/CMR.9.4.499","article-title":"Epidemiology of nosocomial fungal infections","volume":"9","author":"Fridkin","year":"1996","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijantimicag.2011.02.016","article-title":"Candida bloodstream infections: Comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008\u20132009)","volume":"38","author":"Pfaller","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.3201\/eid1910.130393","article-title":"New clonal strain of Candida auris, Delhi, India","volume":"19","author":"Chowdhary","year":"2013","journal-title":"Emerg. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s10096-013-2027-1","article-title":"Multidrug-resistant endemic clonal strain of Candida auris in India","volume":"33","author":"Chowdhary","year":"2014","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/cid\/ciw691","article-title":"Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses","volume":"64","author":"Lockhart","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1128\/JCM.01355-17","article-title":"Thinking beyond the Common Candida Species: Need for Species-Level Identification of Candida Due to the Emergence of Multidrug-Resistant Candida auris","volume":"55","author":"Lockhart","year":"2017","journal-title":"J. Clin. Microbiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"105922","DOI":"10.1016\/j.ijantimicag.2020.105922","article-title":"Pan-resistant Candida auris isolates from the outbreak in New York are susceptible to ibrexafungerp (a glucan synthase inhibitor)","volume":"55","author":"Zhu","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6","DOI":"10.15585\/mmwr.mm6901a2","article-title":"Candida auris Isolates Resistant to Three Classes of Antifungal Medications-New York, 2019","volume":"69","author":"Ostrowsky","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e00578","DOI":"10.1002\/mbo3.578","article-title":"Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen","volume":"7","year":"2018","journal-title":"Microbiologyopen"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Sabino, R., Verissimo, C., Pereira, A.A., and Antunes, F. (2020). Candida auris, an Agent of Hospital-Associated Outbreaks: Which Challenging Issues Do We Need to Have in Mind?. Microorganisms, 8.","DOI":"10.3390\/microorganisms8020181"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.3389\/fmicb.2019.02788","article-title":"Review on Antifungal Resistance Mechanisms in the Emerging Pathogen Candida auris","volume":"10","author":"Chaabane","year":"2019","journal-title":"Front Microbiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/mmy\/myy054","article-title":"Candida auris: The recent emergence of a multidrug-resistant fungal pathogen","volume":"57","author":"Forsberg","year":"2019","journal-title":"Med. Mycol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.3201\/eid2411.180368","article-title":"Candida auris in South Africa, 2012\u20132016","volume":"24","author":"Govender","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3201\/eid2007.131765","article-title":"Candida auris-associated candidemia, South Africa","volume":"20","author":"Magobo","year":"2014","journal-title":"Emerg. Infect. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00005792-200007000-00006","article-title":"Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group","volume":"79","author":"Patterson","year":"2000","journal-title":"Medicine"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/318483","article-title":"Aspergillosis case-fatality rate: Systematic review of the literature","volume":"32","author":"Lin","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1128\/AAC.00233-15","article-title":"Nationwide Surveillance of Azole Resistance in Aspergillus Diseases","volume":"59","author":"Vermeulen","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Snelders, E., van der Lee, H.A., Kuijpers, J., Rijs, A.J., Varga, J., Samson, R.A., Mellado, E., Donders, A.R., Melchers, W.J., and Verweij, P.E. (2008). Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med., 5.","DOI":"10.4016\/8254.01"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1128\/AEM.00231-09","article-title":"Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles","volume":"75","author":"Snelders","year":"2009","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1128\/CMR.8.4.515","article-title":"Cryptococcosis in the era of AIDS\u2013100 years after the discovery of Cryptococcus neoformans","volume":"8","author":"Mitchell","year":"1995","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1086\/526778","article-title":"Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006","volume":"46","author":"Walzer","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199302113280604","article-title":"Idiopathic CD4+ T-lymphocytopenia--four patients with opportunistic infections and no evidence of HIV infection","volume":"328","author":"Duncan","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/QCO.0b013e32834cac17","article-title":"Pneumocystis jirovecii pneumonia in non-HIV-infected patients: New risks and diagnostic tools","volume":"24","author":"Reid","year":"2011","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.2174\/138945012803530107","article-title":"Analysis of current antifungal agents and their targets within the Pneumocystis carinii genome","volume":"13","author":"Porollo","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1550-7408.1994.tb05938.x","article-title":"Evidence for the presence of \u201cmetabolic sterols\u201d in Pneumocystis: Identification and initial characterization of Pneumocystis carinii sterols","volume":"41","author":"Kaneshiro","year":"1994","journal-title":"J. Eukaryot Microbiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"766","DOI":"10.4269\/ajtmh.2010.08-0408","article-title":"Plasmodium falciparum dihydrofolate reductase and dihyropteroate synthase mutations and the use of trimethoprim-sulfamethoxazole prophylaxis among persons infected with human immunodeficiency virus","volume":"82","author":"Malamba","year":"2010","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/11585270-000000000-00000","article-title":"Echinocandin antifungal drugs in fungal infections: A comparison","volume":"71","author":"Chen","year":"2011","journal-title":"Drugs"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/tcrm.2007.3.1.71","article-title":"Comparison of echinocandin antifungals","volume":"3","author":"Eschenauer","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2217\/17460913.3.6.593","article-title":"Anidulafungin: A novel echinocandin for candida infections","volume":"3","author":"Meyer","year":"2008","journal-title":"Future Microbiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1128\/AAC.02145-13","article-title":"Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates","volume":"58","author":"Paderu","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_81","unstructured":"Cushion, M., Ashbaugh, A., Borroto-Esoda, K., Barat, S.A., and Angulo, D. (2018). SCY-078 demonstrates antifungal activity against pneumocystis in a prophylactic murine model of pneumocystis pneumonia. ASM Microbe Online."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1128\/JCM.36.10.2950-2956.1998","article-title":"Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts","volume":"36","year":"1998","journal-title":"J. Clin. Microbiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1128\/AAC.49.7.2851-2856.2005","article-title":"Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins","volume":"49","author":"Maligie","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/jac\/dkx010","article-title":"The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp.","volume":"72","author":"Escribano","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Larkin, E., Hager, C., Chandra, J., Mukherjee, P.K., Retuerto, M., Salem, I., Long, L., Isham, N., Kovanda, L., and Borroto-Esoda, K. (2017). The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.02396-16"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Pfaller, M.A., Messer, S.A., Rhomberg, P.R., Borroto-Esoda, K., and Castanheira, M. (2017). Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.00161-17"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Schell, W.A., Jones, A.M., Borroto-Esoda, K., and Alexander, B.D. (2017). Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.01102-17"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Berkow, E.L., Angulo, D., and Lockhart, S.R. (2017). In Vitro Activity of a Novel Glucan Synthase Inhibitor, SCY-078, against Clinical Isolates of Candida auris. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.00435-17"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Ghannoum, M., Long, L., Isham, N., Hager, C., Wilson, R., Borroto-Esoda, K., Barat, S., and Angulo, D. (2019). Activity of a novel 1,3-beta-D-glucan Synthase Inhibitor, Ibrexafungerp (formerly SCY-078), Against Candida glabrata. Antimicrob. Agents Chemother.","DOI":"10.1128\/AAC.01510-19"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Arendrup, M.C., Jorgensen, K.M., Hare, R.K., and Chowdhary, A. (2020). In Vitro Activity of Ibrexafungerp (SCY-078) against Candida auris Isolates as Determined by EUCAST Methodology and Comparison with Activity against C. albicans and C. glabrata and with the Activities of Six Comparator Agents. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.02136-19"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Zhu, Y.C., Barat, S.A., Borroto-Esoda, K., Angulo, D., Chaturvedi, S., and Chaturvedi, V. (2020). In vitro Efficacy of Novel Glucan Synthase Inhibitor, Ibrexafungerp (SCY-078), Against Multidrug- and Pan-resistant Candida auris Isolates from the Outbreak in New York. BioRxiv.","DOI":"10.1101\/811182"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1177\/00220345010800031101","article-title":"Antifungal resistance of candidal biofilms formed on denture acrylic in vitro","volume":"80","author":"Chandra","year":"2001","journal-title":"J. Dent. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"a019752","DOI":"10.1101\/cshperspect.a019752","article-title":"Mechanisms of Antifungal Drug Resistance","volume":"5","author":"Cowen","year":"2014","journal-title":"Cold Spring Harb. Perspect Med."},{"key":"ref_94","unstructured":"Ghannoum, M., Long, L., Sherif, R., Abidi, F.Z., Borroto-Esoda, K., Barat, S., Angulo, D., and Wiederhold, N. (2020). Determination of Antifungal Activity of SCY-078, a Novel Glucan Synthase Inhibitor, Against a broad panel of Rare Pathogenic Fungi. ASM Microbe Online."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Larkin, E.L., Long, L., Isham, N., Borroto-Esoda, K., Barat, S., Angulo, D., Wring, S., and Ghannoum, M. (2019). A Novel 1,3-Beta-d-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.02611-18"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0966-842X(03)00117-3","article-title":"Antifungal agents: Mechanisms of action","volume":"11","author":"Odds","year":"2003","journal-title":"Trends Microbiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1128\/AAC.00917-07","article-title":"A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus","volume":"51","author":"Rocha","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1128\/AAC.00234-15","article-title":"Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates","volume":"59","author":"Lamoth","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/jac\/dkx422","article-title":"Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata","volume":"73","author":"Wiederhold","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1128\/AAC.04445-14","article-title":"Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model","volume":"59","author":"Lepak","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Wring, S.A., Randolph, R., Park, S., Abruzzo, G., Chen, Q., Flattery, A., Garrett, G., Peel, M., Outcalt, R., and Powell, K. (2017). Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.02068-16"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Ghannoum, M., Isham, N., Angulo, D., Borroto-Esoda, K., Barat, S., and Long, L. (2020). Efficacy of Ibrexafungerp (SCY-078) against Candida auris in an In Vivo Guinea Pig Cutaneous Infection Model. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.00854-20"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Vergidis, P., Clancy, C.J., Shields, R.K., Park, S.Y., Wildfeuer, B.N., Simmons, R.L., and Nguyen, M.H. (2016). Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0153247"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Lee, A., Prideaux, B., Zimmerman, M., Carter, C., Barat, S., Angulo, D., Dartois, V., Perlin, D.S., and Zhao, Y. (2020). Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.02268-19"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.1093\/ofid\/ofx163.1207","article-title":"SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of Invasive Aspergillosis","volume":"4","author":"Barat","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Petraitis, V., Petraitiene, R., Katragkou, A., Maung, B.B.W., Naing, E., Kavaliauskas, P., Barat, S., Borroto-Esoda, K., Azie, N., and Angulo, D. (2020). Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1-->3)-beta-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.02429-19"},{"key":"ref_107","unstructured":"Barat, S.A., Borroto-Esoda, K., Angulo, D., Ashbaugh, A., and Cushion, M. (2021, January 05). Efficacy of Ibrexafungerp (formerly SCY-078) in a Murine Treatment Model of Pneumocystis Pneumonia. ASM Microbe Online. Available online: https:\/\/www.google.com\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwjftpvlt4TvAhWzQEEAHTPRAjUQFjAAegQIAhAD&url=https%3A%2F%2Fd1io3yog0oux5.cloudfront.net%2F_b4b7034c330a452751c9d7c806d956ea%2Fscynexis%2Fdb%2F385%2F2952%2Fpdf%2FBARAT%2BASM2019%2BPneumocystis_final.pdf&usg=AOvVaw3kok9W_OsTJ6m6dJlFXIG_."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1093\/jac\/dkz277","article-title":"MSG-10: A Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis","volume":"74","author":"Spec","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/jcph.1146","article-title":"Lack of Impact by SCY-078, a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions","volume":"58","author":"Wring","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/cpdd.588","article-title":"Clinical Pharmacokinetics and Drug-Drug Interaction Potential for Coadministered SCY-078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus","volume":"8","author":"Wring","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/13543784.2020.1791820","article-title":"Oral Ibrexafungerp: An investigational agent for the treatment of vulvovaginal candidiasis","volume":"29","author":"Azie","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_112","unstructured":"Juneja, D., Singh, O., Tarai, B., and Angulo, D. (2019, January 13\u201316). Successful Treatment of Two Patients with Candida auris Candidemia with the Investigational Agent, Oral Ibrexafungerp (formerly SCY-078) from the CARES Study. Proceedings of the 29th ECCMID Congress, Amsterdam, The Netherlands."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"113S","DOI":"10.1097\/01.AOG.0000558840.33387.ee","article-title":"A Phase 2b, Dose-Finding Study Evaluating Oral Ibrexafungerp vs Fluconazole in Vulvovaginal Candidiasis (DOVE)","volume":"133","author":"Cadet","year":"2019","journal-title":"Obstet. Gynecol."},{"key":"ref_114","first-page":"964","article-title":"Oral ibrexafungerp efficacy and safety in the treatment of vulvovaginal candidiasis: A phase 3, randomized, blinded, study vs. placebo (VANISH-303)","volume":"223","author":"Schwebke","year":"2020","journal-title":"IDSOG Oral Present."},{"key":"ref_115","unstructured":"Scynexis (2020, December 29). SCYNEXIS Announces Positive Top-Line Results from Its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection). SCYNEXIS, Inc. Press Release Online. Available online: https:\/\/www.globenewswire.com\/news-release\/2020\/04\/21\/2019183\/0\/en\/SCYNEXIS-Announces-Positive-Top-Line-Results-from-its-Second-Pivotal-Phase-3-Study-VANISH-306-of-Oral-Ibrexafungerp-for-the-Treatment-of-Vulvovaginal-Candidiasis-Vaginal-Yeast-Infe.html."},{"key":"ref_116","unstructured":"Scynexis (2020, December 29). SCYNEXIS Completes Patient Enrollment Ahead of Schedule in the Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection). SCYNEXIS, Inc. Press Release Online. Available online: https:\/\/www.scynexis.com\/news-media\/press-releases\/detail\/201\/scynexis-completes-patient-enrollment-ahead-of-schedule-in."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Alexander, B.D., Cornely, O.A., Pappas, P.G., Miller, R., Johnson, M., Vazquez, J., Ostrosky-Zeichner, L., Spec, A., Rautemaa-Richardson, R., and Krause, R. (2020, December 29). Efficacy and Safety of Oral Ibrexafungerpin 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI). Poster Presented at ID Week 2020 Online. Available online: https:\/\/www.scynexis.com\/science\/publications-and-presentations\/posters-and-presentations.","DOI":"10.1093\/ofid\/ofaa439.1432"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Wring, S., Borroto-Esoda, K., Solon, E., and Angulo, D. (2019). SCY-078, a Novel Fungicidal Agent, Demonstrates Distribution to Tissues Associated with Fungal Infections during Mass Balance Studies with Intravenous and Oral [(14)C]SCY-078 in Albino and Pigmented Rats. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.02119-18"},{"key":"ref_119","unstructured":"Murphy, G., Hyman, M., Willett, M., and Angulo, D. (2021, January 05). CYP-mediated Drug Interaction Profile of SCY-078, a novel Glucan Synthase Inhibitor (GSI). Poster Presentation, ASM Microbe Online. Available online: https:\/\/www.google.com\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwi75vS8uYTvAhWEi1wKHcfgDTwQFjABegQIARAD&url=https%3A%2F%2Fd1io3yog0oux5.cloudfront.net%2F_55b477ff244a9c3da81d223259d3ec5d%2Fscynexis%2Fdb%2F385%2F2578%2Fpdf%2FPOSTER_CYP-mediated%2BDrug%2BInteraction%2BProfile%2Bof%2BSCY-078%2Ba%2Bnovel%2BGlucan%2BSynthase%2BInhibitor%2B%2528GSI%2529_ASM%2BMicrobe%2B2017.pdf&usg=AOvVaw2CGBLOrIAWaPSRo1h4F1sJ."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1046\/j.1472-8206.2002.00114.x","article-title":"In vitro effects of tacrolimus on human cytochrome P450","volume":"16","author":"Lecointre","year":"2002","journal-title":"Fundam Clin. Pharmacol."},{"key":"ref_121","unstructured":"Scynexis (2020, December 29). SCYNEXIS Announces FDA Acceptance and Priority Review of New Drug Application for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infections. SCYNEXIS, Inc. Press Release Online. Available online: https:\/\/ir.scynexis.com\/press-releases\/detail\/225\/scynexis-announces-fda-acceptance-and-priority-review-of."},{"key":"ref_122","unstructured":"Scynexis (2020, December 29). SCYNEXIS Announces Interim Results from Phase 2 Study of Oral SCY-078 in Patients with Invasive Candidiasis. scyNEXIS, Inc. Press Release Online, Available online: https:\/\/www.scynexis.com\/news-media\/press-releases\/detail\/79\/scynexis-announces-interim-results-from-phase-2-study-of."},{"key":"ref_123","unstructured":"Scynexis (2020, December 29). Ibrexafungerp: First Representative of a Novel Oral\/IV Antifungal Family (vF_SCYX Corporate Presentation-Dec.2020.pdf). Corporate Presentation\u2014Dec. 2020 Online. Available online: https:\/\/www.google.com\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwjtg9GAuYTvAhVfQUEAHTwIBcsQFjAAegQIAhAD&url=https%3A%2F%2Fd1io3yog0oux5.cloudfront.net%2F_3e9cb56306763226218d943b224cb4f9%2Fscynexis%2Fdb%2F334%2F2840%2Fpdf%2FvF_SCYX%2BCorporate%2BPresentation%2B-%2BDec.2020.pdf&usg=AOvVaw2QYCiPbuPvtHgLjRPxjULt."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/jac\/dkw325","article-title":"Global access to antifungal therapy and its variable cost","volume":"71","author":"Kneale","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_125","unstructured":"(2020, December 29). Mycamine (Micafungin Sodium) Injection. Fujisawa Healthcare, Inc. Application No.: 021506. Approval Date: 16 March 2005. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Special Pathogen and Immunologic Drug Products, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2005\/21-506_Mycamine.cfm."},{"key":"ref_126","unstructured":"(2020, December 29). Eraxis (Anidulafungin) Injection. Vicuron Pharmaceuticals Inc. Application No.: 021632 & 021948, 17 February 2006. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Special Pathogen and Immunologic Drug Products, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/021632_021948_EraxisTOC.cfm."},{"key":"ref_127","unstructured":"SAHPRA (2021, January 17). South African Health Products Regulatory Authority Registered Health Products. Available online: https:\/\/www.sahpra.org.za\/registered-health-products\/."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/7\/3\/163\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:28:19Z","timestamp":1760160499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/7\/3\/163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":127,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["jof7030163"],"URL":"https:\/\/doi.org\/10.3390\/jof7030163","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]}}}